Bradley A. Stohr
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Bradley A. Stohr has a total of 94 co-authors. Here are the top co-authors by number of shared publications:
- Emily Chan
Department of Pathology Stanford University School of Medicine Stanford California USA
63 shared publications - Alan Ashworth
Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco
60 shared publications - Anil Parsram Bidkar
Department of Radiology and Biomedical Imaging, University of California, San Francisco, USA
60 shared publications - Brant Delafontaine
Drug Research Unit Ghent, Ghent University Hospital, Ghent, Belgium
60 shared publications - Brian Yu
Amgen Inc., South San Francisco, CA, United States
60 shared publications - Emily A. Egusa
Division of Hematology/Oncology, Department of Medicine, University of California, San Francisco, California
60 shared publications
Latest Publications
- 1 October 2026
- Published by Wiley in Histopathology
Immunohistochemical profile of molecularly verified clear cell renal cell carcinomas
Background: Immunohistochemical (IHC) features of clear cell renal cell carcinomas (CCRCC) have historically been defined by morphologically selected tumours, but aberrant staining patterns that may confound the diagnosis are common. Recent studies have described the prognostic significance of architectural patterns in CCRCC and have proposed grading schemes based on morphology. We investigate a cohort of molecularly verified CCRCC to evaluate their IHC profiles and correlate with architectural patterns and key driver molecular alterations. Methods: Renal cell carcinomas (RCCs) sequenced at our institution between January 2015 and June 2024 by NGS assay were reviewed to identify CCRCCs based on VHL alterations and/or 3p loss. Architectural patterns were classified into low grade (LG) (nested, cystic), intermediate grade (IG) (tubular, tubulopapillary, alveolar), and high grade (HG) (fused nests/solid sheets, rhabdoid, sarcomatoid, low‐grade spindled, pleomorphic tumour giant cells), based on findings from recent studies and scored based on highest‐grade pattern. IHC staining for CA9, KER7, PAX8, and CD10 were reviewed for percent staining (focal 25% or less, moderate 26%–50%, diffuse greater than 50%). Correlation of aberrant staining with primary/metastatic status, architectural patterns, and molecular alterations was analysed. Results: 125 cases of molecularly verified CCRCC were identified and 108 cases with concurrent IHC met inclusion criteria, including 54 primary and 54 metastatic tumours. KER7 positivity was more common in primary vs. metastatic tumours (45% vs. 13%, P = 0.001), in tumours with LG/IG architectural patterns (67% LG and 67% IG vs. 17% HG, P = 0.002) and in PBRM1 wild type (WT) tumours (84% PBRM1 WT vs. 16% PBRM1 mutated, P = 0.021). Negative CA9 staining occurred only in metastatic tumours (15%). PBRM1 mutated tumours were more likely to be KER7‐/CA9+/PAX8‐, while BAP1 mutated tumours were more likely to have higher‐grade architectural patterns and lack CD10 expression. Conclusions: In this cohort of molecularly verified CCRCCS, positive KER7 staining was seen in 30% of tumours with diffuse strong staining in 16%. The IHC profiles correlated with both morphological features and genetic alterations.
- 1 October 2026
- Published by Wiley in Histopathology
Immunohistochemical profile of molecularly verified clear cell renal cell carcinomas
Background: Immunohistochemical (IHC) features of clear cell renal cell carcinomas (CCRCC) have historically been defined by morphologically selected tumours, but aberrant staining patterns that may confound the diagnosis are common. Recent studies have described the prognostic significance of architectural patterns in CCRCC and have proposed grading schemes based on morphology. We investigate a cohort of molecularly verified CCRCC to evaluate their IHC profiles and correlate with architectural patterns and key driver molecular alterations. Methods: Renal cell carcinomas (RCCs) sequenced at our institution between January 2015 and June 2024 by NGS assay were reviewed to identify CCRCCs based on VHL alterations and/or 3p loss. Architectural patterns were classified into low grade (LG) (nested, cystic), intermediate grade (IG) (tubular, tubulopapillary, alveolar), and high grade (HG) (fused nests/solid sheets, rhabdoid, sarcomatoid, low‐grade spindled, pleomorphic tumour giant cells), based on findings from recent studies and scored based on highest‐grade pattern. IHC staining for CA9, KER7, PAX8, and CD10 were reviewed for percent staining (focal 25% or less, moderate 26%–50%, diffuse greater than 50%). Correlation of aberrant staining with primary/metastatic status, architectural patterns, and molecular alterations was analysed. Results: 125 cases of molecularly verified CCRCC were identified and 108 cases with concurrent IHC met inclusion criteria, including 54 primary and 54 metastatic tumours. KER7 positivity was more common in primary vs. metastatic tumours (45% vs. 13%, P = 0.001), in tumours with LG/IG architectural patterns (67% LG and 67% IG vs. 17% HG, P = 0.002) and in PBRM1 wild type (WT) tumours (84% PBRM1 WT vs. 16% PBRM1 mutated, P = 0.021). Negative CA9 staining occurred only in metastatic tumours (15%). PBRM1 mutated tumours were more likely to be KER7‐/CA9+/PAX8‐, while BAP1 mutated tumours were more likely to have higher‐grade architectural patterns and lack CD10 expression. Conclusions: In this cohort of molecularly verified CCRCCS, positive KER7 staining was seen in 30% of tumours with diffuse strong staining in 16%. The IHC profiles correlated with both morphological features and genetic alterations.
- Open Access
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
FigureS5 from Immunotherapeutic Targeting and PET Imaging of DLL3 in Small-Cell Neuroendocrine Prostate Cancer
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigureS5 from Immunotherapeutic Targeting and PET Imaging of DLL3 in Small-Cell Neuroendocrine Prostate Cancer
- Open Access
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
FigureS6 from Immunotherapeutic Targeting and PET Imaging of DLL3 in Small-Cell Neuroendocrine Prostate Cancer
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigureS6 from Immunotherapeutic Targeting and PET Imaging of DLL3 in Small-Cell Neuroendocrine Prostate Cancer
- Open Access
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary MovieS1c from Immunotherapeutic Targeting and PET Imaging of DLL3 in Small-Cell Neuroendocrine Prostate Cancer
Supplemental Movies 1a-1d: 22Rv1-LacZ and 22Rv1-DLL3 cells co-cultures. Time-lapse movies of 22Rv1-LacZ and 22Rv1-DLL3 cells (labeled with NuclightRed) co-cultured with T cells and either NT control BiTE® or AMG 757. T cells were plated at an E:T ratio of 5:1. Images were captured every 6 hours at 10x magnification. a. 22Rv1-LacZ cells and T cells treated with NT control BiTE®. b. 22Rv1-DLL3 cells and T cells treated with NT control BiTE®. c. 22Rv1-LacZ cells and T cells treated with AMG 757. d. 22Rv1-DLL3 cells and T cells treated with AMG 757.
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary MovieS1c from Immunotherapeutic Targeting and PET Imaging of DLL3 in Small-Cell Neuroendocrine Prostate Cancer
Supplemental Movies 1a-1d: 22Rv1-LacZ and 22Rv1-DLL3 cells co-cultures. Time-lapse movies of 22Rv1-LacZ and 22Rv1-DLL3 cells (labeled with NuclightRed) co-cultured with T cells and either NT control BiTE® or AMG 757. T cells were plated at an E:T ratio of 5:1. Images were captured every 6 hours at 10x magnification. a. 22Rv1-LacZ cells and T cells treated with NT control BiTE®. b. 22Rv1-DLL3 cells and T cells treated with NT control BiTE®. c. 22Rv1-LacZ cells and T cells treated with AMG 757. d. 22Rv1-DLL3 cells and T cells treated with AMG 757.
- Open Access
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
FigureS3 from Immunotherapeutic Targeting and PET Imaging of DLL3 in Small-Cell Neuroendocrine Prostate Cancer
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigureS3 from Immunotherapeutic Targeting and PET Imaging of DLL3 in Small-Cell Neuroendocrine Prostate Cancer
- Open Access
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Data Figures and Legends from Immunotherapeutic Targeting and PET Imaging of DLL3 in Small-Cell Neuroendocrine Prostate Cancer
Supplementary Data: Figures and Legends combined
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data Figures and Legends from Immunotherapeutic Targeting and PET Imaging of DLL3 in Small-Cell Neuroendocrine Prostate Cancer
Supplementary Data: Figures and Legends combined
- Open Access
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary MovieS 1a from Immunotherapeutic Targeting and PET Imaging of DLL3 in Small-Cell Neuroendocrine Prostate Cancer
Supplemental Movies 1a-1d: 22Rv1-LacZ and 22Rv1-DLL3 cells co-cultures. Time-lapse movies of 22Rv1-LacZ and 22Rv1-DLL3 cells (labeled with NuclightRed) co-cultured with T cells and either NT control BiTE® or AMG 757. T cells were plated at an E:T ratio of 5:1. Images were captured every 6 hours at 10x magnification. a. 22Rv1-LacZ cells and T cells treated with NT control BiTE®. b. 22Rv1-DLL3 cells and T cells treated with NT control BiTE®. c. 22Rv1-LacZ cells and T cells treated with AMG 757. d. 22Rv1-DLL3 cells and T cells treated with AMG 757.
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary MovieS 1a from Immunotherapeutic Targeting and PET Imaging of DLL3 in Small-Cell Neuroendocrine Prostate Cancer
Supplemental Movies 1a-1d: 22Rv1-LacZ and 22Rv1-DLL3 cells co-cultures. Time-lapse movies of 22Rv1-LacZ and 22Rv1-DLL3 cells (labeled with NuclightRed) co-cultured with T cells and either NT control BiTE® or AMG 757. T cells were plated at an E:T ratio of 5:1. Images were captured every 6 hours at 10x magnification. a. 22Rv1-LacZ cells and T cells treated with NT control BiTE®. b. 22Rv1-DLL3 cells and T cells treated with NT control BiTE®. c. 22Rv1-LacZ cells and T cells treated with AMG 757. d. 22Rv1-DLL3 cells and T cells treated with AMG 757.
- Open Access
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
FigureS1 from Immunotherapeutic Targeting and PET Imaging of DLL3 in Small-Cell Neuroendocrine Prostate Cancer
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigureS1 from Immunotherapeutic Targeting and PET Imaging of DLL3 in Small-Cell Neuroendocrine Prostate Cancer
- Open Access
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary MovieS2c from Immunotherapeutic Targeting and PET Imaging of DLL3 in Small-Cell Neuroendocrine Prostate Cancer
Supplemental Movies 2a-2c: 22Rv1-NuclightGreen and SHP-77-NuclightRed mixed population co-cultures. Time-lapse movies of 22Rv1 cells (labeled with NuclightGreen) and SHP-77 cells (labeled with NuclightRed) co-cultured with T cells. Both the 22Rv1 and SHP-77 cells were plated at equal densities and treated with either NT control BiTE®, AMG 757, or the PSMA-targeting HLE BiTE, AMG 160. T cells were added to each well at an E:T ratio of 10:1. Images were captured every 4 hours at 4x magnification for 5 days. a. 22Rv1, SHP-77, and T cells co-cultured with NT control BiTE®. b. 22Rv1, SHP-77, and T cells co-cultured with AMG 757. c. 22Rv1, SHP-77, and T cells co-cultured with AMG 160.
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary MovieS2c from Immunotherapeutic Targeting and PET Imaging of DLL3 in Small-Cell Neuroendocrine Prostate Cancer
Supplemental Movies 2a-2c: 22Rv1-NuclightGreen and SHP-77-NuclightRed mixed population co-cultures. Time-lapse movies of 22Rv1 cells (labeled with NuclightGreen) and SHP-77 cells (labeled with NuclightRed) co-cultured with T cells. Both the 22Rv1 and SHP-77 cells were plated at equal densities and treated with either NT control BiTE®, AMG 757, or the PSMA-targeting HLE BiTE, AMG 160. T cells were added to each well at an E:T ratio of 10:1. Images were captured every 4 hours at 4x magnification for 5 days. a. 22Rv1, SHP-77, and T cells co-cultured with NT control BiTE®. b. 22Rv1, SHP-77, and T cells co-cultured with AMG 757. c. 22Rv1, SHP-77, and T cells co-cultured with AMG 160.
- Open Access
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary MovieS1b from Immunotherapeutic Targeting and PET Imaging of DLL3 in Small-Cell Neuroendocrine Prostate Cancer
Supplemental Movies 1a-1d: 22Rv1-LacZ and 22Rv1-DLL3 cells co-cultures. Time-lapse movies of 22Rv1-LacZ and 22Rv1-DLL3 cells (labeled with NuclightRed) co-cultured with T cells and either NT control BiTE® or AMG 757. T cells were plated at an E:T ratio of 5:1. Images were captured every 6 hours at 10x magnification. a. 22Rv1-LacZ cells and T cells treated with NT control BiTE®. b. 22Rv1-DLL3 cells and T cells treated with NT control BiTE®. c. 22Rv1-LacZ cells and T cells treated with AMG 757. d. 22Rv1-DLL3 cells and T cells treated with AMG 757.
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary MovieS1b from Immunotherapeutic Targeting and PET Imaging of DLL3 in Small-Cell Neuroendocrine Prostate Cancer
Supplemental Movies 1a-1d: 22Rv1-LacZ and 22Rv1-DLL3 cells co-cultures. Time-lapse movies of 22Rv1-LacZ and 22Rv1-DLL3 cells (labeled with NuclightRed) co-cultured with T cells and either NT control BiTE® or AMG 757. T cells were plated at an E:T ratio of 5:1. Images were captured every 6 hours at 10x magnification. a. 22Rv1-LacZ cells and T cells treated with NT control BiTE®. b. 22Rv1-DLL3 cells and T cells treated with NT control BiTE®. c. 22Rv1-LacZ cells and T cells treated with AMG 757. d. 22Rv1-DLL3 cells and T cells treated with AMG 757.